Skip to main content

Month: July 2020

Vopak reports on HY1 2020 financial results

 Highlights for HY1 2020 -excluding exceptional items-:EBITDA of EUR 403 million (HY1 2019: EUR 423 million pre-divestments). Adjusted for EUR 3 million negative currency translation effects and the impact of the divestments of the terminals in Algeciras, Amsterdam and Hamburg (EUR 35 million decrease), EBITDA increased by EUR 18 million (4%), reflecting resilient business performance including the effect of contango oil markets, IMO 2020 converted capacity and reduced chemicals throughput.Occupancy rate subsidiaries of 86% (HY1 2019: 85%) reflects support from contango developments in the oil markets in Q2, whereas storage demand in other market segments remained robust. Planned inspection and maintenance out-of-service capacity at subsidiaries was 1.4 million cbm in Q2 2020. Proportional occupancy rate of 88% (HY1 2019: 84%) included...

Continue reading

CGG: CGG annonce ses résultats du deuxième trimestre 2020

CGG annonce ses résultats du deuxième trimestre 2020Un trimestre marqué par l’impact du Covid-19 et la baisse du prix du pétroleAjustement rapide de la structure des coûtsPARIS, France – 29 juillet 2020 – CGG (ISIN: FR0013181864), leader mondial dans les Géosciences, annonce ses résultats consolidés, non-audités, du T2 2020.Sophie Zurquiyah, Directeur Général de CGG, a déclaré :« Le marché des géosciences a poursuivi sa détérioration ce trimestre, les clients redéfinissant leurs portefeuilles à la suite d’une nouvelle révision en baisse de leurs dépenses E&P. Nos priorités restent centrées sur la sécurité de nos employés, la préservation de la trésorerie et la bonne continuité opérationnelle de nos opérations, par ailleurs excellente ce trimestre malgré la propagation mondiale du COVID-19. Nous mettons en place rapidement les mesures...

Continue reading

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia

COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortalityThe study is the first global, randomised, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this settingRoche remains committed to continuing the Actemra/RoActemra clinical trial programme in COVID-19 to further explore Actemra/RoActemra in other treatment settings, including in combination with an antiviralBasel, 29 July – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III COVACTA study of Actemra®/RoActemra® (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia. In addition, the key secondary endpoints,...

Continue reading

Solvay 2020 first half results: Record cash generation and cost reductions help to weather the storm

July 29, 2020 at 7 a.mSolvay 2020 first half resultsRecord cash generation and cost reductions help to weather the stormHighlightsStrong Free Cash Flow to shareholders from continuing operations of €435 million in the first half, up significantly versus €33 million in the first half 2019, with Q2 contributing €233 million.  The increase was predominantly driven by disciplined working capital management.Net Sales of €4,649 million in the first half were down 11% versus first half 2019, with headwinds from aero, auto, oil & gas, and construction markets impacting volumes since April.  More resilient markets, including healthcare, agro/food, home and personal care and electronics helped to offset some of the challenged markets.  Net sales in Q2 were down 18% to €2,175 million as result of the lower volumes.Acceleration of cost savings...

Continue reading

Resultaten van het eerste halfjaar 2020: Record cash generatie en kostenreducties helpen om de storm te doorstaan

29 juli 2020 om 7u00Resultaten van het eerste halfjaar 2020Record cash generatie en kostenreducties helpen om de storm te doorstaanMarkante feitenSterke vrije kasstroom aan aandeelhouders van voortgezette bedrijfsactiviteiten van €435 miljoen in het eerste halfjaar (waaraan Q2 €233 miljoen bijdroeg), een aanzienlijke stijging ten opzichte van €33 miljoen in het eerste halfjaar van 2019. De stijging werd voornamelijk gedreven door een gedisciplineerd werkkapitaalbeheer.De netto-omzet van €4 649 miljoen in H1 2020 was 11% lager dan in H1 2019, door tegenwind in de vliegtuig-, auto-, olie- & gasmarkten en in de bouwsector die de volumes vanaf april beïnvloedde. De meer veerkrachtige markten, waaronder de gezondheidszorg, agro/voeding, huishoudelijke en persoonlijke verzorging en elektronica, boden juist enige compensatie voor sommige...

Continue reading

Résultats du premier semestre 2020: Génération de cash record et réductions de coûts aident à surmonter la tempête

29 juillet 2020 à 7h00Résultats du premier semestre 2020Génération de cash record et réductions de coûts aident à surmonter la tempêteFaits marquantsFree cash flow aux actionnaires des activités poursuivies en forte hausse qui ressort à 435 M€ sur ce premier semestre contre 33 M€ à la même période en 2019, dont 233 M€ réalisés au second trimestre 2020. Cette performance a été majoritairement réalisée grâce à la gestion rigoureuse du fonds de roulement.Chiffre d’affaires du premier semestre ressort à 4 649 M€, en baisse de -11 % par rapport au S1 2019. Depuis le mois d’avril dernier, le recul des volumes a impacté les secteurs de l’aéronautique, de l’automobile, du pétrole et du gaz et la construction. Les secteurs de la santé, de l’agroalimentaire, des soins à la personne et la maison, et de l’électronique se sont révélés...

Continue reading

MISE À DISPOSITION DES INFORMATIONS RELATIVES AUX CARACTÉRISTIQUES NOTAMMENT JURIDIQUES, FINANCIÈRES ET COMPTABLES D’INGENICO GROUP

Ce communiqué ne constitue pas une offre d’acquérir des titresCOMMUNIQUÉ DU 29 JUILLET 2020 ÉTABLI PARINGENICO GROUPRELATIFÀ L’OFFRE PUBLIQUE MIXTE À TITRE PRINCIPAL, ASSORTIE À TITRE SUBSIDIAIRE D’UNE OFFRE PUBLIQUE D’ÉCHANGE ET D’UNE OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ INGENICO DANS LA LIMITE GLOBALE DE 81% EN ACTIONS WORLDLINE ET 19% EN NUMÉRAIRE1ETÀ L’OFFRE PUBLIQUE ALTERNATIVE MIXTE ET D’ACHAT VISANT LES OBLIGATIONS À OPTION DE CONVERSION ET/OU D’ÉCHANGE EN ACTIONS INGENICO NOUVELLES ET/OU EXISTANTES(LES « OCEANES »)INITIÉES PAR LA SOCIÉTÉWORLDLINEMISE À DISPOSITION DES INFORMATIONS RELATIVES AUX CARACTÉRISTIQUES NOTAMMENT JURIDIQUES, FINANCIÈRES ET COMPTABLES D’INGENICO GROUPLe présent communiqué est diffusé par Ingenico Group (« Ingenico ») conformément aux dispositions de l’article 231-28 du règlement général...

Continue reading

AVAILABILITY OF INFORMATION RELATING IN PARTICULAR TO THE LEGAL, FINANCIAL AND ACCOUNTING CHARACTERISTICS OF INGENICO GROUP

This press release does not constitute an offer to acquire securitiesPRESS RELEASE DATED JULY 29, 2020 PREPARED BYINGENICO GROUPRELATING TOTHE MIXED TENDER OFFER AS THE PRIMARY OFFER, ALONGSIDE A SECONDARY EXCHANGE OFFER AND A SECONDARY CASH OFFER FOR THE INGENICO SHARES UP TO AN OVERALL LIMIT OF 81% IN WORLDLINE SHARES AND 19% IN CASH1ANDTHE ALTERNATIVE MIXED AND CASH OFFER FOR BONDS CONVERTIBLE INTO AND/OR EXCHANGEABLE FOR NEW AND/OR EXISTING INGENICO SHARES(THE “OCEANEs”)INITIATED BYWORLDLINEAVAILABILITY OF INFORMATION RELATING IN PARTICULAR TO THE LEGAL, FINANCIAL AND ACCOUNTING CHARACTERISTICS OF INGENICO GROUPThis press release is distributed by Ingenico Group (“Ingenico”) in accordance with the provisions of Article 231-28 of the AMF General Regulation. In accordance with Article L.621-8 of the French Monetary and Financial Code...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.